Calmare Therapeutics Incorporated to Present at the Robins Equity Research Round-up Conference
October 7, 2015
Presentation: Thursday, October 8th at noon PDT
Location: Skamania Lodge, Stevenson, Washington

Fairfield, CT – October 7, 2015 – Calmare Therapeutics Incorporated, (OTCQB: CTTC) (CTI), the Calmare® pain mitigation company, announced today that Calmare Therapeutics President and CEO Conrad Mir will be presenting the Calmare Therapeutics story at the Robins Equity Research Round-up taking place October 8-10, 2015.

The Calmare presentation is scheduled for Thursday, October 8th, at Noon PDT. The presentation will not be simulcast but rather be recorded and offered to the public for review early next week on the Catalyst website as well as Calmare Therapeutics website. The Robins Equity Research Roundup is presented by Catalyst Research Management Group –RIA.

“We are honored and thrilled to have Calmare Therapeutics participate in the Robins Equity Research Round-up and look forward to welcoming them back for years to come,” said Marc Robins CFA, president of Catalyst Research Management.

The conference is being held at the Skamania Lodge, nestled in the Cascade Range Gorge above the Columbia River. The Robins Equity Round-up is a small-cap investor conference introducing new and interesting company equities and their management team to clients and potential shareholders. The audience will include investors and brokers from the region as well as professional money managers from different parts of the country.

About the Company

Calmare Therapeutics Incorporated, the Calmare Pain Mitigation Therapy company, researches, develops and commercializes its flagship medical device - the non-invasive and non-addictive Calmare® Pain Therapy device. The company holds the U.S. Food & Drug Administration 510k clearance (#K081255) on its device, which grants it the exclusive right to sell, market, research and develop the medical device. Calmare devices are commercially sold to medical practices throughout the world. Devices are also found on U.S. military hospitals, clinics and installations via CTI’s General Services Administration (GSA) military contract (#V797P-4300B).

Forward-Looking Statement

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.

Direct inquiries to
Conrad F. Mir
Calmare Therapeutics Incorporated
2 Trap Falls Rd. STE 507
Shelton, CT 06484
Email: This email address is protected. Javascript must be enabled to view it.
Tel: 203.712.7893